var data={"title":"Midazolam: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Midazolam: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6581?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">see &quot;Midazolam: Drug information&quot;</a> and <a href=\"topic.htm?path=midazolam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Midazolam: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709086\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Respiratory depression and personnel/equipment for monitoring and resuscitation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings; airway obstruction, desaturation, hypoxia, and apnea have also been reported, most often when used concomitantly with other CNS depressants (eg, opioids). In some cases, where this was not recognized promptly and treated effectively, death or hypoxic encephalopathy has resulted. Midazolam should be used only in hospital or ambulatory care settings, including physicians' and dentists' offices, that can provide for continuous monitoring of respiratory and cardiac function (ie, pulse oximetry). Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured. For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with opioids:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Individualization of dosage (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam must never be used without individualization of dosage. The initial intravenous dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a healthy adult. Lower doses are necessary for older (over 60 years) or debilitated patients and in patients receiving concomitant opioids or other CNS depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 mg/mL or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonates (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam should not be administered by rapid injection in the neonatal population. Severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant use of fentanyl.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49990988\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Midazolam+SyrSpend SF PH4</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196443\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Midazolam Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054079\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Benzodiazepine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Benzodiazepine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hypnotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443890\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage must be individualized and based on patient's age, underlying diseases, concurrent medications, and desired effect; decrease dose (by ~30%) if opioids or other CNS depressants are administered concomitantly. Patients receiving ECMO may require higher doses due to drug absorption in the ECMO circuit (Mulla 2000). To minimize excipient load, preservative free preparations should be used; alternatively use the more concentrated midazolam injection (eg, 5 mg/mL) and dilute with SWI without preservatives.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Sedation, intermittent dosing or procedural (intubation): </b> IM, IV: 0.05 to 0.1 mg/kg/dose over 5 minutes (Kumar 2010; VanLooy 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Sedation, mechanically ventilated patient:</b> IV: <b>Note:</b> Use the lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: Continuous IV infusion: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA &le;32 weeks: Initial: 0.03 mg/kg/<b>hour</b> (0.5 <b>mcg</b>/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA &gt;32 weeks: Initial: 0.06 mg/kg/<b>hour</b> (1 <b>mcg</b>/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alternative dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GA &lt;34 weeks: <b>Note:</b> Some have recommended against the use of a loading or bolus dose due to associated hypotension; to rapidly achieve sedation, it has been suggested to begin the continuous infusion at a faster rate for the first several hours (Jacqz-Aigrain 1992). Others have successfully used loading doses of 0.2 mg/kg given over 1 hour to prevent hypotension (Anand 1999; Treluyer 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GA &ge;34 weeks: 0.2 mg/kg/dose once (Anand 1999; Jacqz-Aigrain 1990; Treluyer 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous IV infusion (Anand 1999; Jacqz-Aigrain 1994; Treluyer 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GA 24 to 26 weeks: Initial: 0.02 to 0.03 mg/kg/<b>hour</b> (0.33 to 0.5 <b>mcg</b>/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GA 27 to 29 weeks: Initial: 0.03 to 0.04 mg/kg/<b>hour</b> (0.5 to 0.67 <b>mcg</b>/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GA &ge;30 weeks: Initial: 0.03 to 0.06 mg/kg/<b>hour</b> (0.5 to 1 <b>mcg</b>/kg/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> After prolonged therapy, consider a slow wean of therapy to prevent signs and symptoms of withdrawal. The following regimen has been reported: If duration of therapy &le;4 days, wean over at least 2 days beginning with an initial dosage reduction of 30% to 50% followed by 20% to 30% dosage reductions every 6-8 hours; monitor closely for signs and symptoms of withdrawal with each reduction in dose. If duration of therapy is &gt;4 days, decrease infusion rate by 25% to 50% every 12 hours, then convert to an intermittent dose every 4 hours and lastly, every 8 hours (Anand 1999). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Seizures, refractory; status epilepticus: </b>IV: Dosage regimens variable, reported doses are higher than sedative doses: <b>Note:</b> Consider omitting loading dose if patient has received an IV dose of a benzodiazepine; begin continuous IV infusion at lower end of range and titrate to lowest effective dose: Loading dose: 0.06 to 0.15 mg/kg/dose followed by a continuous infusion of 0.06 to 0.4 mg/kg/<b>hour</b> (1 to 7 <b>mcg</b>/kg/minute); maximum reported rate: 1.1 mg/kg/<b>hour</b> (18 mcg/kg/minute) (Boylan 2004; Conde 2005; Holmes 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054071\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">see &quot;Midazolam: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage must be individualized and based on patient's age, underlying diseases, concurrent medications, and desired effect; decrease dose (by &sim;30%) if opioids or other CNS depressants are administered concomitantly; use multiple small doses and titrate to desired sedative effect; allow 3 to 5 minutes between doses to decrease the chance of oversedation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation, anxiolysis, and amnesia prior to procedure or before induction of anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Infants, Children and Adolescents: Usual: 0.1 to 0.15 mg/kg 30-60 minutes before surgery or procedure; range: 0.05 to 0.15 mg/kg; doses up to 0.5 mg/kg have been used in more anxious patients; maximum total dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 1 to 5 months: Limited data available in nonintubated infants; infants &lt;6 months are at higher risk for airway obstruction and hypoventilation; titrate dose with small increments to desired clinical effect; monitor carefully </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 6 months to Children 5 years: Initial: 0.05 to 0.1 mg/kg; titrate dose carefully; total dose of 0.6 mg/kg may be required; usual total dose maximum: 6 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 12 years: Initial: 0.025 to 0.05 mg/kg; titrate dose carefully; total doses of 0.4 mg/kg may be required; usual total dose maximum: 10 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 12 to 16 years: Dose as adults; usual total dose maximum: 10 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: Limited data available: <b>Note:</b> Some investigators suggest premedication with intranasal lidocaine to decrease irritation and subsequent agitation (Chiaretti 2011; Lugo 1993):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 1 to 5 months: 0.2 mg/kg (single dose) (Harcke 1995; Mittal 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;6 months, Children, and Adolescents: 0.2 to 0.3 mg/kg (maximum single dose: 10 mg); may repeat in 5 to 15 minutes to a maximum of 0.5 mg/kg (maximum total dose: 10 mg) (Acworth 2001; Charetti 2011; Harcke 1995; Lane 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Infants &gt;6 months, Children, and Adolescents &le;16 years: Single dose: 0.25 to 0.5 mg/kg once, depending on patient status and desired effect, usual: 0.5 mg/kg; maximum dose: 20 mg; <b>Note:</b>  Younger patients (6 months to &lt;6 years) and those less cooperative may require higher doses (up to 1 mg/kg); use lower initial doses (0.25 mg/kg) in patients with cardiac or respiratory compromise, concomitant CNS depressant, or high-risk surgical patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Limited data available: Infants &gt;6 months and Children: Usual: 0.25-0.5 mg/kg once (Krauss 2006); doses up to 1 mg/kg have been used in infants and young children (7 months to 5 years of age) but may be associated with a higher incidence of postprocedural agitation (Kanegaye 2003; Tanaka 2000) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation, mechanically ventilated patient: </b> Infants, Children, and Adolescents: IV: Loading dose: 0.05 to 0.2 mg/kg given slow IV over 2 to 3 minutes, then follow with initial continuous IV infusion: 0.06 to 0.12 mg/kg/<b>hour</b> (1 to 2 <b>mcg</b>/kg/minute); titrate to the desired effect; range: 0.024 to 0.36 mg/kg/<b>hour</b> (0.4 to 6 <b>mcg</b>/kg/minute) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures, acute treatment:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Buccal: Reserve for patients without IV access (Ashrafi 2010; Kutlu 2003; McIntyre 2005; Mpimbaza 2008; Talukdar 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: Infants &ge;3 months, Children, and Adolescents: 0.2 to 0.5 mg/kg once; maximum dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\"> Age-based dosing (McIntyre 2005):  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants 6 to 11 months: 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 1 to 4 years: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 5 to 9 years: 7.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &ge;10 years: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Infants, Children, and Adolescents: 0.2 mg/kg/dose; repeat every 10 to 15 minutes; maximum dose: 6 mg  (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal (Bhattachyaryya 2006; Fi&#351;gin 2000; Fi&#351;gin 2002; Holsti 2007; Holsti 2010; Kutlu 2000): Reserve for patients without IV access; divide dose between nares:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 1 to 5 months: 0.2 mg/kg once; maximum dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &ge;6 months: 0.2 mg/kg; one study used 0.3 mg/kg (n=9); maximum dose: 10 mg; may repeat once to a total maximum of 0.4 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures, refractory; status epilepticus refractory to standard therapy: </b> Limited data available: IV (Hayashi 2007; Hegenbarth 2008; Igartua 1999; Koul 1997; Koul 2002; Morrison 2006; Morrison 2008; Ozdemir 2005; Rivera 1993; Singh 2002; Yoshikawa 2000): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 0.15 to 0.2 mg/kg; 0.5 mg/kg/dose was used in one high-dose midazolam study (n=17); consider using the lower end of the loading dose range in patients with hemodynamic instability or who have received other agents with hypotensive effects </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial rate: 0.06 to 0.12 mg/kg/<b>hour</b> (1 to 2 mcg/kg/minute); increase rate every 15 minutes in increments of 0.06 to 0.12 mg/kg/<b>hour</b> (1 to 2 mcg/kg/minute) until seizure activity ceases; one high dose study increased by 0.24 mg/kg/<b>hour</b> (4 mcg/kg/minute); mean required dosage across a number of studies: 0.11 to 0.84 mg/kg/<b>hour</b> (1.87 to 14 mcg/kg/minute); the upper end of this range was used in one study; however, patients were titrated to burst suppression on EEG; maximum reported dose (n=1): 3 mg/kg/<b>hour</b> (50 mcg/kg/minute) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures, status epilepticus, prehospital treatment:</b>  Limited data available: <b>Note:</b> Administered by paramedics when convulsions last &gt;5 minutes or if convulsions are occurring after having intermittent seizures without regaining consciousness for &gt;5 minutes: IM: Children and Adolescents (Silbergleit 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;13 kg: Not studied </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to 40 kg: 5 mg once </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: 10 mg once</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthesia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\"> Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Unpremedicated patients: 0.3 to 0.35 mg/kg (up to 0.6 mg/kg in resistant cases)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Premedicated patients: 0.15 to 0.35 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 0.05 to 0.3 mg/kg as needed, or continuous IV infusion 0.25 to 1.5 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation, preoperative:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 0.07 to 0.08 mg/kg 30 to 60 minutes prior to surgery/procedure; usual dose: 5 mg; <b>Note:</b> Reduce dose in patients with COPD, high-risk patients, patients &ge;60 years of age, and patients receiving other opioids or CNS depressants.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.02 to 0.04 mg/kg; repeat every 5 minutes as needed to desired effect or up to 0.1 to 0.2 mg/kg\t</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation, procedural (moderate):</b>  IV: Initial: 0.5 to 2 mg slow IV over at least 2 minutes; slowly titrate to effect by repeating doses every 2 to 3 minutes if needed; usual total dose: 2.5 to 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Healthy Adults &lt;60 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: Some patients respond to doses as low as 1 mg; no more than 2.5 mg should be administered over a period of 2 minutes. Additional doses of midazolam may be administered after a 2-minute waiting period and evaluation of sedation after each dose increment. A total dose &gt;5 mg is generally not needed. If opioids or other CNS depressants are administered concomitantly, the midazolam dose should be reduced by 30%. A reduced dose is required for patients &ge;60 years, debilitated, or chronically ill.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 25% of dose used to reach sedative effect</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation in mechanically ventilated patients: </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: Initial dose: 0.01 to 0.05 mg/kg (~0.5 to 4 mg); may repeat at 5- to 15-minute intervals until adequate sedation achieved; maintenance infusion: 0.02 to 0.1 mg/kg/<b>hour</b>. Titrate to reach desired level of sedation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Alternative dosing:</b> Initial dose: 0.02 to 0.08 mg/kg (~1 to 5 mg in 70 kg adult); may repeat at 5- to 15-minute intervals until adequate sedation achieved; maintenance infusion: 0.04 to 0.2 mg/kg/<b>hour</b>. Titrate to reach desired level of sedation (Jacobi 2002). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus, refractory:</b> <b>Note:</b> Intubation required; adjust dose based on hemodynamics, seizure activity, and EEG. IV: 0.15 to 0.3 mg/kg (usual dose: 5 to 15 mg); may repeat every 10 to 15 minutes as needed <b>or</b> 0.2 mg/kg bolus followed by a continuous infusion of 0.05 to 0.6 mg/kg/<b>hour</b> (Lowenstein 2005; Meierkord 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus, prehospital treatment:</b> <b>Note:</b> Administered by paramedics when convulsions last &gt;5 minutes or if convulsions are occurring after having intermittent seizures without regaining consciousness for &gt;5 minutes: IM: 10 mg once (Silbergleit 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196415\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL (2 mL); 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 5 mg/mL (1 mL); 10 mg/2 mL (2 mL); 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL (2 mL); 5 mg/5 mL (5 mL); 5 mg/mL (1 mL); 10 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/100 mL (100 mL); 25 mg/100 mL (100 mL); 50 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL in NaCl 0.9% (2 mL [DSC]); 4 mg/2 mL in NaCl 0.9% (2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Midazolam+SyrSpend SF PH4: 1 mg/mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (118 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196399\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027222\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">see &quot;Midazolam: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Midazolam+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196491\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054084\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Buccal: A buccal formulation is not currently available in the US. Some trials used an injectable solution administered buccally. International studies used a 10 mg/mL commercially available buccal formulation. Administer to the buccal mucosa between the gums and the cheek using an oral syringe; gently massage cheek; dose may be divided to both sides of the mouth. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intranasal: Administer using a needleless syringe into the nares over 15 to 30 seconds; use the 5 mg/mL injection; <sup>1</sup>/<sub>2</sub> of the dose may be administered to each nare; <b>Note:</b> The 5 mg/mL injection has also been administered as a nasal spray using a graded pump device (Ljungman 2000) or using an atomizer such as the MAD Nasal Drug delivery device (Holsti 2007; Holsti 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer on empty stomach (feeding is usually contraindicated prior to sedation for procedures). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Avoid extravasation; do not administer intra-arterially</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV (bolus, loading doses, intermittent therapy): Administer by slow IV injection at a concentration of 1 to 5 mg/mL over at least 2 to 5 minutes. In adults: For induction of anesthesia, may administer IV push over 20 to 30 seconds per the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: Rapid administration (&lt;2 minutes) has been reported to cause severe hypotension especially if administered concurrently with fentanyl. For procedural sedation (eg, intubation) or intermittent sedation dosing, administration over at least 2 to 5 minutes has been used, monitor for hypotension (Cloherty 2012). For loading doses, administration over 1 hour have successfully prevented hypotension in neonates (Anand 1999; Treluyer 2005); manufacturer recommends against loading doses in neonates and suggests using a faster continuous infusion rate for the first several hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous IV infusion: Administer via an infusion pump.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer undiluted deep IM into large muscle, generally into anterior-lateral aspect of thigh (vastus lateralis) in pediatric patients (Lam 2005; Malamed 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rectal: Clinical trials utilized parenteral midazolam for rectal administration; administer a 1 to 5 mg/mL solution through a small, lubricated catheter or tube inserted rectally; hold buttocks closed for ~5 minutes after administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472926\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV Infusion:</b> 0.1 mg/mL <b>or</b> 0.5 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472925\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.5 mg/mL <b>or</b> 1 mg/mL  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196437\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). A final concentration of midazolam 0.5 mg/mL is stable for up to 24 hours when diluted with D5W or NS or 4 hours when diluted with LR. A final concentration of 1 mg/mL in NS has been documented to be stable for up to 10 days (McMullin 1995) and up to 27 days in D5W (Karlage 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054083\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Sedation, anxiolysis, amnesia prior to procedures or before induction of anesthesia (FDA approved in ages &ge;6 months to &lt;16 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Preprocedure sedation, anxiolysis, amnesia for diagnostic or radiographic procedures (FDA approved in infants, children, adolescents, and adults); continuous IV sedation of intubated and mechanically ventilated patients (FDA approved in all ages); has also been used for status epilepticus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buccal: Has been used for acute treatment of seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Has been used for preprocedure sedation, anxiolysis, amnesia for diagnostic or radiographic procedures; acute treatment of seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Has been used for preprocedure sedation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196498\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Versed may be confused with VePesid, Vistaril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV, oral administration for sedation in children) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196495\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in adults unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness, drug dependence (physical and psychological dependence with prolonged use), headache, myoclonus (preterm infants), seizure-like activity (children), severe sedation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Hiccups (more common in adults), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (severity less than diazepam), pain at injection site (severity less than diazepam)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Nystagmus (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea (children), bradypnea, cough, decreased tidal volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Paradoxical reaction (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acidic taste, agitation, amnesia, bigeminy, bradycardia, bronchospasm, confusion, delirium (emergence), dyspnea, euphoria, hallucination, hyperventilation, laryngospasm, sialorrhea, skin rash, tachycardia, ventricular premature contractions, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196422\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to midazolam or any component of the formulation; intrathecal or epidural injection of parenteral forms containing preservatives (ie, benzyl alcohol); use in premature infants for parenteral forms containing benzyl alcohol; acute narrow-angle glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent use of oral midazolam with protease inhibitors (atazanavir, atazanavir-cobicistat, darunavir, indinavir, lopinavir-ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir); concurrent use of oral or injectable midazolam with fosamprenavir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for benzodiazepines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to benzodiazepines; acute pulmonary insufficiency; severe chronic obstructive pulmonary disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196403\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiorespiratory effects: <b>[US Boxed Warning]: Has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings; airway obstruction, desaturation, hypoxia, and apnea have also been reported, most often when used concomitantly with other CNS depressants (eg, opioids). In some cases, death or hypoxic encephalopathy resulted. Use only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory and cardiac function (ie, pulse oximetry). Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.</b> Risk of cardiorespiratory adverse events is increased in patients with abnormal airway anatomy, cyanotic congenital heart disease, sepsis or severe pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). A minimum of 1 day should elapse after midazolam administration before attempting these tasks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause hypotension, particularly in pediatric patients or patients with hemodynamic instability. Hypotension may occur more frequently in patients who have received opioid analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Paradoxical reactions: Paradoxical reactions, including agitation, hyperactive or aggressive behavior, involuntary movements (including tonic/clonic movements and muscle tremor) and combativeness have been reported with benzodiazepines. Consideration should be given to the possibility of cerebral hypoxia or true paradoxical reactions. Should such reactions occur, the response to each dose of midazolam and all other drugs, including local anesthetics, should be evaluated before proceeding. May consider treatment with flumazenil (Massanari 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: Use IV midazolam with caution in patients with uncompensated acute illnesses, such as severe fluid or electrolyte disturbances.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure. Adverse hemodynamic events have been reported in pediatric patients with cardiovascular instability; avoid rapid IV administration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with glaucoma; contraindicated in patients with acute narrow angle glaucoma; may use in patients with open-angle glaucoma only if receiving appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; half-life of midazolam and metabolites may be prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease (eg, COPD); these patients may be sensitive to the respiratory depressant effects of midazolam.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant use with opioids: <b>[US Boxed Warning]: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; decreased dosages recommended. These patients take longer to recover completely after midazolam administration for the induction of anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; decreased dosages recommended. These patients take longer to recover completely after midazolam administration for the induction of anesthesia. Use of oral midazolam is not recommended in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obese patients: Use benzodiazepines with caution in obese patients; may have prolonged action when discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Injection: <b>[US Boxed Warning]: Do not administer by rapid IV injection in neonates; severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant fentanyl use.</b> Neonates are also vulnerable to profound and/or prolonged respiratory effects of midazolam.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Pediatric patients with cardiac or respiratory compromise may be sensitive to the respiratory depressant effect of midazolam. Pediatric patients undergoing procedures involving the upper airway (eg, upper endoscopy, dental care) are vulnerable to episodes of desaturation and hypoventilation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: <b>[US Boxed Warning]: Midazolam must never be used without individualization of dosage. The initial IV dose for sedation in adults may be as little as 1 mg, but should not exceed 2.5 mg in a healthy adult. Lower doses are necessary for older (&gt;60 years of age) or debilitated patients and in patients receiving concomitant opioids or other CNS depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 mg/mL or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Does not protect against increases in intracranial pressure, heart rate, and/or blood pressure during intubation. Do not use in shock, coma, or acute alcohol intoxication with depression of vital signs. Avoid intra-arterial administration or extravasation of parenteral formulation. Use during upper airway procedures (ie, endoscopy, dental care) may increase risk of hypoventilation. Prolonged responses have been noted following extended administration by continuous infusion (possibly due to metabolite accumulation) or in the presence of drugs which inhibit midazolam metabolism. Oral midazolam is intended for use in monitored settings only and not for chronic or home use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Midazolam is a short half-life benzodiazepine and may be of benefit in patients where a rapidly and short-acting agent is desired (acute agitation). Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative and anticonvulsant effects. It does not develop to the anxiolytic effects (Vinkers 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Withdrawal symptoms (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating) may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017184\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child&rsquo;s or fetus&rsquo; brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer&rsquo;s labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In neonates, particularly premature neonates, several cases of myoclonus (rhythmic myoclonic jerking) have been reported (~8% incidence).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196481\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196408\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12611&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Midazolam. Management: Oral midazolam contraindicated with antihepaciviral combination products. When used with intravenous midazolam, monitor for increased midazolam effects (eg, sedation, respiratory depression) and consider using a reduced midazolam dose.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Midazolam.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Midazolam. Management: Oral midazolam use is contraindicated with cobicistat-containing products.  IV midazolam should be used with caution, close monitoring, and consideration of lower IV midazolam doses.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May decrease the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated.  Use intravenous midazolam with great caution in patients receiving itraconazole, employing reduced initial doses whenever possible and monitoring closely for enhanced and prolonged effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Midazolam.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Midazolam. Management: Consider an alternative less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A metabolism (e.g., lorazepam, oxazepam) are similarly less likely to interact.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Midazolam. Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roxithromycin: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Midazolam. Management: Use of oral midazolam with telaprevir is contraindicated.  IV midazolam use may pose a lower risk, but dose reductions should be considered and patients should be monitored closely for signs/symptoms of toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofisopam: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196439\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase serum concentrations of midazolam. Management: Avoid concurrent use of grapefruit juice with oral midazolam.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196410\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196425\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Midazolam has been found to cross the human placenta and can be detected in the serum of the umbilical vein and artery, as well as the amniotic fluid. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines (Bergman 1992, Iqbal 2002, Wikner 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with midazolam during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women should not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054078\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Level of sedation, respiratory rate, heart rate, blood pressure, oxygen saturation (ie, pulse oximetry)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196402\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors (Brunton 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196421\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IM: Sedation: Children: Within 5 minutes; Adults: ~15 minutes; IV: 3 to 5 minutes; Oral: 10 to 20 minutes; Intranasal: Children: 5.55 &plusmn; 2.22 minutes (Lee-Kim 2004); Adults: Within 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peak effect: IM: Children: 15 to 30 minutes; Adults: 30 to 60 minutes; IV: 3 to 5  minutes; Intranasal: Children: 10 minutes (al-Rakaf 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IM: Up to 6 hours; Mean: 2 hours; Intranasal: Children: 23.1 minutes (Chiaretti 2011); IV: Single dose: &lt;2 hours (dose-dependent) (Fragen 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Rapid, complete; Oral, Intranasal: Rapid (Lee-Kim 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely distributed in body including CSF; V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 1.1 L/kg (range: 0.4 to 4.2 L/kg) (de Wildt 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 6 months to 16 years: 1.24 to 2.02 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1 to 3.1 L/kg; increased in females, elderly, and obesity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97%, primarily albumin; in patients with cirrhosis, protein binding is reduced with a free fraction of ~5% (Trouvin 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic CYP3A4; 60% to 70% of biotransformed midazolam is the active metabolite 1-hydroxy-midazolam (or alpha-hydroxymidazolam)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 40% to 50% (Kanto 1985), ~36% (children); IM: &gt;90%; Intranasal: Children: ~60%; Rectal: Children: ~40% to 65% (mean: 52%) (Clausen 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prolonged in cirrhosis, congestive heart failure, obesity, renal failure, and elderly.<b> Note:</b> In patients with renal failure, reduced elimination of active hydroxylated metabolites leads to drug accumulation and prolonged sedation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 6.3 hours (range: 2.6 to 17.7 hours) (de Wildt 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 4 to 12 hours; seriously ill neonates: 6.5 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: IV: 2.9 to 4.5 hours; Syrup: 2.2 to 6.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 3 hours (range: 1.8 to 6.8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 0.5 to 1 hour; Oral: 0.17 to 2.65 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: IV: Urine (primarily as metabolites); Oral: Urine (~90% within 24 hours; primarily [60% to 70%] as glucuronide conjugates of the hydroxylated metabolites; &lt;0.03% as unchanged drug); feces (~2% to 10% over 5 days) (Kanto 1985; Smith 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 1.8 mL/minute/kg (range: 0.7 to 6.7 mL/minute/kg) (de Wildt 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &lt;39 weeks GA: 1.17 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &gt;39 weeks GA: 1.84 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Seriously ill neonates: 1.2 to 2 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;3 months: 9.1 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;1 year: 3.2 to 13.3 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Healthy adults: 4.2 to 9 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with acute renal failure: 1.9 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054089\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of injection: 0.14 mEq/mL. Midazolam is 3 to 4 times as potent as diazepam.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323409\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Midazolam HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/2 mL (2 mL): $1.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $1.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $3.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $2.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (5 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/10 mL (10 mL): $7.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Midazolam HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/100 mL 0.9% (100 mL): $20.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $47.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Midazolam HCl-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/100 mL 0.9% (100 mL): $18.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $31.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Midazolam+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (120 mL): $437.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Midazolam HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (118 mL): $81.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196427\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anespar (ID);</li>\n      <li>Buccolam (ES, GB, IE, IL, MT);</li>\n      <li>Dalam (AR, JO, PY);</li>\n      <li>Diormicum (SV);</li>\n      <li>Domi (MY);</li>\n      <li>Doricum (VE);</li>\n      <li>Dormicum (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, IQ, IR, IS, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NI, NL, OM, PA, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VN, YE, ZA, ZM, ZW);</li>\n      <li>Dormicum[inj.] (HR);</li>\n      <li>Dormid (PH);</li>\n      <li>Dormilat (BD);</li>\n      <li>Dormitol (LK);</li>\n      <li>Dormizol (PH);</li>\n      <li>Dormonid (BR, CL, PE);</li>\n      <li>Fulsed (CN, IN, VN);</li>\n      <li>Hipnoz (ID);</li>\n      <li>Hypnofast (HK);</li>\n      <li>Hypnovel (AU, BE, CO, FR, GB, IE, NZ);</li>\n      <li>Hypozam (PH);</li>\n      <li>Ipnovel (IT);</li>\n      <li>Midacum (ZA);</li>\n      <li>Midafresa (JP);</li>\n      <li>Midazo (TW);</li>\n      <li>Midolam (IL);</li>\n      <li>Midozor (MX);</li>\n      <li>Miloz (ID);</li>\n      <li>Mizolam (BD, MY);</li>\n      <li>Nok (BD);</li>\n      <li>Omida (TW);</li>\n      <li>Relacum (MX);</li>\n      <li>Sedacum (ID, LK, PH);</li>\n      <li>Sedoz (PH);</li>\n      <li>Sopnil (BD);</li>\n      <li>Uzolam (TW);</li>\n      <li>Versed (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011;117(2, pt 1):420-421. doi:10.1097/AOG.0b013e31820eede9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acworth JP, Purdie D, and Clark RC, &quot;Intravenous Ketamine Plus Midazolam Is Superior to Intranasal Midazolam for Emergency Paediatric Procedural Sedation,&quot; <i>Emerg Med J</i>, 2001, 18(1):39-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11310461/pubmed\" target=\"_blank\" id=\"11310461\">11310461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrian ER, &ldquo;Intranasal Versed&reg;: The Future of Pediatric Conscious Sedation,&rdquo; <i>Pediatr Nurs</i>, 1994, 20(3):287-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/8008480/pubmed\" target=\"_blank\" id=\"8008480\">8008480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anand KJ, Barton BA, McIntosh N, et al, &quot;Analgesia and Sedation in Preterm Neonates Who Require Ventilatory Support: Results From the NOPAIN Trial. Neonatal Outcome and Prolonged Analgesia in Neonates,&quot; <i>Arch Pediatr Adolesc Med</i>, 1999, 153(4):331-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/10201714/pubmed\" target=\"_blank\" id=\"10201714\">10201714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashrafi MR, Khosroshahi N, Karimi P, et al, &quot;Efficacy and Usability of Buccal Midazolam in Controlling Acute Prolonged Convulsive Seizures in Children,&quot; <i>Eur J Paediatr Neurol</i>, 2010, 14(5):434-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/20554464/pubmed\" target=\"_blank\" id=\"20554464\">20554464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergman U, Rosa FW, Baum C, et al, &quot;Effects of Exposure to Benzodiazepine During Fetal Life,&quot; <i>Lancet</i>, 1992, 340(8821):694-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/1355799/pubmed\" target=\"_blank\" id=\"1355799\">1355799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhattacharyya M, Kalra V, and Gulati S, &quot;Intranasal Midazolam vs Rectal Diazepam in Acute Childhood Seizures,&quot; <i>Pediatr Neurol</i>, 2006, 34(5):355-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/16647994/pubmed\" target=\"_blank\" id=\"16647994\">16647994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Booker PD, Beechey A, and Lloyd-Thomas AR, &ldquo;Sedation of Children Requiring Artificial Ventilation Using an Infusion of Midazolam,&rdquo; <i>Br J Anaesth</i>, 1986, 58(10):1104-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/3533120/pubmed\" target=\"_blank\" id=\"3533120\">3533120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boylan GB, Rennie JM, Chorley G, et al, &quot;Second-Line Anticonvulsant Treatment of Neonatal Seizures: A Video-EEG Monitoring Study,&quot; <i>Neurology</i>, 2004, 62(3):486-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/14872039/pubmed\" target=\"_blank\" id=\"14872039\">14872039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burtin P, Jacqz-Aigrain E, Girard P, et al, &ldquo;Population Pharmacokinetics of Midazolam in Neonates,&rdquo; <i>Clin Pharmacol Ther</i>, 1994, 56(6 Pt 1):615-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/7995003/pubmed\" target=\"_blank\" id=\"7995003\">7995003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castro Conde JR, Hern&aacute;ndez Borges AA, Dom&eacute;nech Mart&iacute;nez E, et al, &quot;Midazolam in Neonatal Seizures With No Response to Phenobarbital,&quot; <i>Neurology</i>, 2005, 64(5):876-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/15753426/pubmed\" target=\"_blank\" id=\"15753426\">15753426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiaretti A, Barone G, Rigante D, et al, &quot;Intranasal Lidocaine and Midazolam for Procedural Sedation in Children,&quot; <i>Arch Dis Child</i>, 2011, 96(2):160-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/21030365/pubmed\" target=\"_blank\" id=\"21030365\">21030365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Wildt SN, Kearns GL, Hop WC, et al, &ldquo;Pharmacokinetics and Metabolism of Intravenous Midazolam in Preterm Infants,&rdquo; <i>Clin Pharmacol Ther</i>, 2001, 70(6):525-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11753268 /pubmed\" target=\"_blank\" id=\"11753268 \">11753268 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fi&#351;gin T, G&uuml;rer Y, Senbil N, et al, &quot;Nasal Midazolam Effects on Childhood Acute Seizures,&quot; <i>J Child Neurol</i>, 2000, 15(12):833-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11198507/pubmed\" target=\"_blank\" id=\"11198507\">11198507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fi&#351;gin T, Gurer Y, Tezi&ccedil; T, et al, &quot;Effects of Intranasal Midazolam and Rectal Diazepam on Acute Convulsions in Children: Prospective Randomized Study,&quot; <i>J Child Neurol</i>, 2002, 17(2):123-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11952072/pubmed\" target=\"_blank\" id=\"11952072\">11952072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harcke HT, Grissom LE, and Meister MA, &quot;Sedation in Pediatric Imaging Using Intranasal Midazolam,&quot; <i>Pediatr Radiol</i>, 1995, 25(5):341-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/7567258/pubmed\" target=\"_blank\" id=\"7567258\">7567258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hayashi K, Osawa M, Aihara M, et al, &quot;Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood,&quot; <i>Pediatr Neurol</i>, 2007, 36(6):366-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/17560497/pubmed\" target=\"_blank\" id=\"17560497\">17560497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes GL and Riviello JJ Jr, &quot;Midazolam and Pentobarbital for Refractory Status Epilepticus,&quot; <i>Pediatr Neurol</i>, 1999, 20(4):259-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/10328273/pubmed\" target=\"_blank\" id=\"10328273\">10328273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holsti M, Sill BL, Firth SD, et al, &quot;Prehospital Intranasal Midazolam for the Treatment of Pediatric Seizures,&quot; <i>Pediatr Emerg Care</i>, 2007, 23(3):148-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/17413428/pubmed\" target=\"_blank\" id=\"17413428\">17413428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holsti M, Dudley N, Schunk J, et al, &quot;Intranasal Midazolam vs Rectal Diazepam for the Home Treatment of Acute Seizures in Pediatric Patients With Epilepsy,&quot; <i>Arch Pediatr Adolesc Med</i>, 2010, 164(8):747-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/20679166/pubmed\" target=\"_blank\" id=\"20679166\">20679166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsu AJ, Carson KA, Yung R, et al, &ldquo;Severe Prolonged Sedation Associated with Coadministration of Protease Inhibitors and Intravenous Midazolam During Bronchoscopy,&rdquo; <i>Pharmacotherapy</i>, 2012, 32(6):538-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/22488554/pubmed\" target=\"_blank\" id=\"22488554\">22488554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Igartua J, Silver P, Maytal J, et al, &quot;Midazolam Coma for Refractory Status Epilepticus in Children,&quot; <i>Crit Care Med</i>, 1999, 27(9):1982-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/10507628/pubmed\" target=\"_blank\" id=\"10507628\">10507628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iqbal MM, Sobhan T, Ryals T, et al, &quot;Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,&quot; <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11773648/pubmed\" target=\"_blank\" id=\"11773648\">11773648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobi J, Fraser GL, Coursin DB, et al, &quot;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&quot; <i>Crit Care Med</i>, 2002, 30(1):119-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11902253/pubmed\" target=\"_blank\" id=\"11902253\">11902253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacqz-Aigrain E, Daoud P, Burtin P, et al, &quot;Pharmacokinetics of Midazolam During Continuous Infusion in Critically Ill Neonates,&quot; <i>Eur J Clin Pharmacol</i>, 1992, 42(3):329-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/1577053/pubmed\" target=\"_blank\" id=\"1577053\">1577053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacqz-Algrain E, Daoud P, Burtin P, et al, &ldquo;Placebo-Controlled Trial of Midazolam Sedation in Mechanically Ventilated Newborn Babies,&rdquo; <i>Lancet</i>, 1994, 344(8923):646-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/7915348 /pubmed\" target=\"_blank\" id=\"7915348 \">7915348 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacqz-Aigrain E, Wood C, and Robieux I, &quot;Pharmacokinetics of Midazolam in Critically Ill Neonates,&quot; <i>Eur J Clin Pharmacol</i>, 1990, 39(2):191-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/2253674/pubmed\" target=\"_blank\" id=\"2253674\">2253674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/22504099/pubmed\" target=\"_blank\" id=\"22504099\">22504099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koitabashi T, Satoh N, Takino Y. Intravenous midazolam passage into breast milk. <i>J Anesth</i>. 1997;11:242-243.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koul R, Chacko A, Javed H, et al, &quot;Eight-Year Study of Childhood Status Epilepticus: Midazolam Infusion in Management and Outcome,&quot; <i>J Child Neurol</i>, 2002, 17(12):908-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/12593465/pubmed\" target=\"_blank\" id=\"12593465\">12593465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koul R, Raj Aithala G, Chacko A, et al, &quot;Continuous Midazolam Infusion as Treatment of Status Epilepticus,&quot; <i>Arch Dis Child</i>, 1997, 76(5):445-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/9196363/pubmed\" target=\"_blank\" id=\"9196363\">9196363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/16517277 /pubmed\" target=\"_blank\" id=\"16517277 \">16517277 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al, &quot;Premedication for Nonemergency Endotracheal Intubation in the Neonate,&quot; <i>Pediatrics</i>, 2010, 125(3):608-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kupietzky A and Houpt MI, &ldquo;Midazolam: A Review of Its Use for Conscious Sedation of Children,&rdquo; <i>Pediatr Dent</i>, 1993, 15(4):237-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/8247896/pubmed\" target=\"_blank\" id=\"8247896\">8247896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kutlu NO, Yakinci C, Dogrul M, et al, &quot;Intranasal Midazolam for Prolonged Convulsive Seizures,&quot; <i>Brain Dev</i>, 2000, 22(6):359-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11042416/pubmed\" target=\"_blank\" id=\"11042416\">11042416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam C, Udin RD, Malamed SF, et al, &quot;Midazolam Premedication in Children: A Pilot Study Comparing Intramuscular and Intranasal Administration,&quot; <i>Anesth Prog</i>, 2005, 52(2):56-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/16048152/pubmed\" target=\"_blank\" id=\"16048152\">16048152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lane RD and Schunk JE, &quot;Atomized Intranasal Midazolam Use for Minor Procedures in the Pediatric Emergency Department,&quot; <i>Pediatr Emerg Care</i>, 2008, 24(5):300-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/18496113/pubmed\" target=\"_blank\" id=\"18496113\">18496113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ljungman G, Kreuger A, Andreasson S, et al, &ldquo;Midazolam Nasal Spray Reduces Procedural Anxiety in Children,&rdquo; <i>Pediatrics</i>, 2000, 105(1 Pt 1):73-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/10617707/pubmed\" target=\"_blank\" id=\"10617707\">10617707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lowenstein DH, &quot;Treatment Options for Status Epilepticus,&quot;<i> Curr Opin Pharmacol</i>, 2005, 5(3):334-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/15907922/pubmed\" target=\"_blank\" id=\"15907922\">15907922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Fishbein M, Nahata MC, et al, &ldquo;Complication of Intranasal Midazolam,&rdquo; <i>Pediatrics</i>, 1993, 92(4):638.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/8414846 /pubmed\" target=\"_blank\" id=\"8414846 \">8414846 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magny JF, Zupan V, Dehan M, et al, &ldquo;Midazolam and Myoclonus in Neonate,&rdquo; <i>Eur J Pediatr</i>, 1994, 153(5):389-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/8033934 /pubmed\" target=\"_blank\" id=\"8033934 \">8033934 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malamed SF, Quinn CL, and Hatch HG, &quot;Pediatric Sedation With Intramuscular and Intravenous Midazolam,&quot; <i>Anesth Prog</i>, 1989, 36(4-5):155-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/2490015/pubmed\" target=\"_blank\" id=\"2490015\">2490015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malinovsky JM, Populaire C, Cozian A, et al, &ldquo;Premedication With Midazolam in Children, Effect of Intranasal, Rectal and Oral Routes on Plasma Midazolam Concentrations,&rdquo; <i>Anaesthesia</i>, 1995, 50(4):351-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/7747857 /pubmed\" target=\"_blank\" id=\"7747857 \">7747857 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massanari M, Novitsky J, and Reinstein LJ, &ldquo;Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,&rdquo; <i>Clin Pediatr</i>, 1997, 36(12):681-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/9415834 /pubmed\" target=\"_blank\" id=\"9415834 \">9415834 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matheson I, Lunde PK, Bredesen JE, et al, &quot;Midazolam and Nitrazepam in the Maternity Ward: Milk Concentrations and Clinical Effects,&quot; <i>Br J Clin Pharmacol</i>, 1990, 30(6):787-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/2288825/pubmed\" target=\"_blank\" id=\"2288825\">2288825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntyre J, Robertson S, Norris E, et al, &quot;Safety and Efficacy of Buccal Midazolam Versus Rectal Diazepam for Emergency Treatment of Seizures in Children: A Randomised Controlled Trial,&quot; <i>Lancet</i>, 2005, 366(9481):205-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/16023510/pubmed\" target=\"_blank\" id=\"16023510\">16023510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meierkord H, Boon P, Engelsen B, et al, &quot;EFNS Guideline on the Management of Status Epilepticus in Adults,&quot;<i> Eur J Neurol</i>, 2010, 17(3):348-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/20050893/pubmed\" target=\"_blank\" id=\"20050893\">20050893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mittal P, Manohar R, and Rawat AK, &quot;Comparative Study of Intranasal Midazolam and Intravenous Diazepam Sedation for Procedures and Seizures,&quot;<i> Indian J Pediatr</i>, 2006, 73(11):975-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/17127776/pubmed\" target=\"_blank\" id=\"17127776\">17127776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morrison GC and Whitehouse WP, &quot;High-Dose Midazolam in Convulsive Status Epilepticus,&quot; <i>Pediatr Neurol</i>, 2008, 39(3):221.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/18725073/pubmed\" target=\"_blank\" id=\"18725073\">18725073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morrison G, Gibbons E, and Whitehouse WP, &quot;High-Dose Midazolam Therapy for Refractory Status Epilepticus in Children,&quot; <i>Intensive Care Med</i>, 2006, 32(12):2070-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/16977485/pubmed\" target=\"_blank\" id=\"16977485\">16977485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mpimbaza A, Ndeezi G, Staedke S, et al, &quot;Comparison of Buccal Midazolam With Rectal Diazepam in the Treatment of Prolonged Seizures in Ugandan Children: A Randomized Clinical Trial,&quot; <i>Pediatrics</i>, 2008, 121(1):58-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/18166545/pubmed\" target=\"_blank\" id=\"18166545\">18166545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulla H, Lawson G, Woodland ED, et al, &quot;Effects of Neonatal Extracorporeal Membrane Oxygenation Circuits on Drug Disposition,&quot; <i>Curr Ther Res Clin Exp</i>, 2000, 61:838-48.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/25147175 /pubmed\" target=\"_blank\" id=\"25147175 \">25147175 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozdemir D, Gulez P, Uran N, et al, &quot;Efficacy of Continuous Midazolam Infusion and Mortality in Childhood Refractory Generalized Convulsive Status Epilepticus,&quot; <i>Seizure</i>, 2005, 14(2):129-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/15694567/pubmed\" target=\"_blank\" id=\"15694567\">15694567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riva J, Lejbusiewicz G, Papa M, et al, &ldquo;Oral Premedication With Midazolam in Paediatric Anaesthesia. Effects on Sedation and Gastric Contents,&rdquo; <i>Paediatr Anaesth</i>, 1997, 7(3):191-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/9189963/pubmed\" target=\"_blank\" id=\"9189963\">9189963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rivera R, Segnini M, Baltodano A, et al, &ldquo;Midazolam in the Treatment of Status Epilepticus in Children,&rdquo; <i>Crit Care Med</i>, 1993, 21(7):991-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/8319479/pubmed\" target=\"_blank\" id=\"8319479\">8319479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22579258\"></a>Shergill AK, Ben-Menachem T, Chandrasekhara V, et al. Guidelines for endoscopy in pregnant and lactating women. <i>Gastrointest Endosc</i>. 2012;76(1):18-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/22579258/pubmed\" target=\"_blank\" id=\"22579258\">22579258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silbergleit R, Durkalski V, Lowenstein D, et al, &quot;Intramuscular Versus Intravenous Therapy for Prehospital Status Epilepticus,&quot; <i>N Engl J Med</i>, 2012, 366(7):591-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/22335736/pubmed\" target=\"_blank\" id=\"22335736\">22335736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silvasi DL, Rosen DA, and Rosen KR, &ldquo;Continuous Intravenous Midazolam Infusion for Sedation in the Pediatric Intensive Care Unit,&rdquo; <i>Anesth Analg</i>, 1988, 67(3):286-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/3344980 /pubmed\" target=\"_blank\" id=\"3344980 \">3344980 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh N, Pandey RK, Saksena AK, et al, &quot;A Comparative Evaluation of Oral Midazolam With Other Sedatives as Premedication in Pediatric Dentistry,&quot; <i>J Clin Pediatr Dent</i>, 2002, 26(2):161-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/11874008/pubmed\" target=\"_blank\" id=\"11874008\">11874008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talukdar B and Chakrabarty B, &quot;Efficacy of Buccal Midazolam Compared to Intravenous Diazepam in Controlling Convulsions in Children: A Randomized Controlled Trial,&quot;<i> Brain Dev</i>, 2009, 31(10):744-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/19114297/pubmed\" target=\"_blank\" id=\"19114297\">19114297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treluyer JM, Zohar S, Rey E, et al, &quot;Minimum Effective Dose of Midazolam for Sedation of Mechanically Ventilated Neonates,&quot; <i>J Clin Pharm Ther</i>, 2005, 30(5):479-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/16164495/pubmed\" target=\"_blank\" id=\"16164495\">16164495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    VanLooy JW, Schumacher RE, and Bhatt-Mehta V, &quot;Efficacy of a Premedication Algorithm for Nonemergent Intubation in a Neonatal Intensive Care Unit,&quot; <i>Ann Pharmacother</i>, 2008, 42(7):947-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/18594052/pubmed\" target=\"_blank\" id=\"18594052\">18594052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/22536226/pubmed\" target=\"_blank\" id=\"22536226\">22536226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang Z, Gorski JC, Hamman MA, et al, &ldquo;The Effects of St John's Wort (<i>Hypericum perforatum</i>) on Human Cytochrome P450 Activity,&rdquo; <i>Clin Pharmacol Ther</i>, 2001, 70(4):317-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/ 11673747 /pubmed\" target=\"_blank\" id=\" 11673747 \"> 11673747 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN, Stiller CO, Bergman U, et al, &quot;Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,&quot; <i>Pharmacoepidemiol Drug Saf</i>, 2007, 16(11):1203-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/17894421/pubmed\" target=\"_blank\" id=\"17894421\">17894421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa H, Yamazaki S, Abe T, et al, &quot;Midazolam as a First-Line Agent for Status Epilepticus in Children,&quot; <i>Brain Dev</i>, 2000, 22(4):239-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-pediatric-drug-information/abstract-text/10838111/pubmed\" target=\"_blank\" id=\"10838111\">10838111</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12611 Version 219.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709086\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F49990988\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F196443\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054079\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443890\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054071\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196415\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F196399\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50027222\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F196491\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054084\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14472926\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472925\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F196437\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054083\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196498\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196495\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196422\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196403\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017184\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F196481\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F196408\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F196439\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196410\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196425\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054078\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196402\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F196421\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1054089\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323409\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196427\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12611|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">Midazolam: Drug information</a></li><li><a href=\"topic.htm?path=midazolam-patient-drug-information\" class=\"drug drug_patient\">Midazolam: Patient drug information</a></li></ul></div></div>","javascript":null}